Why can you buy NMN as a supplement but not CBD? Why was NAC pulled from some online stores, then restored? Why does red yeast rice rarely list how much of its key compound it contains? The answer to all of these is a little-known part of US supplement law usually called "drug preclusion" or the "drug exclusion" clause.

In simple terms, it is a race. If a substance was approved as a drug, or seriously studied as one, before anyone sold it as a supplement or food, it generally cannot be sold as a supplement. This guide explains how the rule works, how the FDA decides who won the race, the ingredients it has affected, the debate over whether it is fair, and what it means for you. For the November 2026 NAC decision specifically, see our post on the FDA's proposed NAC rule.

The short version

  • It is a race to market. An ingredient approved as a drug, or authorized for drug trials that are substantial and public, before it was marketed as a supplement or food is generally excluded from supplements.
  • The law has two ways out. Show that supplement or food marketing came first, or have the FDA issue a regulation allowing the ingredient. The first such regulation, for NAC, was proposed in November 2026 and is not yet final.
  • The rule has shaped real products: NAC (drug in 1963), NMN (excluded in 2022, no longer excluded since 2025), CBD (still excluded), red yeast rice made to contain lovastatin (treated as an unapproved drug) and pyridoxamine (excluded).
  • The fight is over the details. The FDA uses the date a drug trial application took effect, which is usually confidential, and judges case by case whether trials were "substantial." Supplement groups say that is unpredictable; supporters say the rule protects drug development and drug review.
  • For you: a "supplement" can contain a drug ingredient. Treat red yeast rice like the statin it resembles, and check with your doctor or pharmacist about interactions.

Drug preclusion at a glance

IngredientWhat came firstStatus as of November 2026
NACApproved as a drug (Mucomyst) in 1963; supplement ads from 1991Excluded, but sold under FDA enforcement discretion; a rule to allow it was proposed in November 2026
NMNFDA found US supplement sales from 2017, before the drug investigationNot excluded since the FDA reversed itself in September 2025
CBDPublic drug trials and the 2018 approval of EpidiolexExcluded; the FDA says a new regulatory pathway is needed and it would work with Congress on one
Red yeast riceIts monacolin K is identical to lovastatin (Mevacor, approved 1987)Products with enhanced or added lovastatin are treated as unapproved drugs; traditional red yeast rice is sold
Pyridoxamine (a vitamin B6 form)Drug trial application filed in 1999Excluded since the FDA's 2009 decision
VinpocetineDrug trial authorization in 1981Tentatively excluded in 2016; no final decision found; still sold

Details and sources for each case are below.

What the drug preclusion rule says

The Dietary Supplement Health and Education Act of 1994 (DSHEA) defines what a dietary supplement is. One clause, section 201(ff)(3)(B) of the Food, Drug, and Cosmetic Act, says a supplement may not include an ingredient that was:

  • approved as a new drug,
  • certified as an antibiotic,
  • licensed as a biologic, or
  • "authorized for investigation as a new drug" with "substantial clinical investigations" that have been started and made public,

unless the ingredient was "marketed as a dietary supplement or as a food" before that approval or authorization. A separate provision, section 301(ll), bars adding approved drugs and publicly investigated drugs to foods, and because supplements legally count as foods, the FDA says it applies to supplements as well.

The law also works in the other direction. If an ingredient was sold as a supplement first and later approved as a drug, it can generally stay on the supplement market.

There are two ways for an excluded ingredient to get back in:

  • Prove it came first. Show that it was marketed as a supplement or food before the drug approval or authorization. The FDA counts only marketing in the US.
  • An FDA regulation. The FDA can issue a regulation, after public comment, finding the ingredient lawful. It did not use this power for more than 30 years; the first proposal, for NAC, was published on November 17, 2026.

Why Congress wrote it

According to the FDA's reading of the law and its history, the clause has two purposes. The first is "to prevent manufacturers from escaping appropriate safety and efficacy review and FDA oversight for drugs by classifying these products as dietary supplements." When DSHEA was debated in 1994, Senator Tom Harkin, one of its sponsors, said the compromise "assures that prescription drugs cannot escape appropriate review and oversight by being classified as dietary supplements."

The second is "to protect the incentives for new drug development." Drug trials are expensive. If a company could fund that research and then watch the same molecule appear in cheap supplements, the incentive to study it as a medicine would shrink.

The FDA says the law lets it make an exception only when two conditions are met: regulating the ingredient as a supplement would still provide adequate safeguards, and allowing it would be unlikely to hold back new drug development.

How the FDA decides who came first

Most of the controversy is in the details. Based on the FDA's guidance and its recent decisions:

  • The drug side's date is when its trial application took effect. The FDA says "authorized for investigation" means an investigational new drug application (IND) "that has gone into effect." The FDA does not disclose an IND that has not already been made public, so a supplement company usually cannot check these dates. In its NMN decision, the FDA said it was "prohibited from disclosing" IND details.
  • "Substantial" is judged case by case. In its 2025 NMN decision the FDA said "substantial" means trials of "qualitative importance" for drug development, that size is only one factor, that some early studies can qualify, and that "a one-size-fits-all definition is not appropriate." Critics say that leaves no bright line.
  • The supplement side must show US marketing. The law does not say "in the United States," but the FDA reads it that way, so in its view sales in other countries do not count. Supplement groups dispute this. Simply being present in food is not enough either: the guidance says showing the substance "was present as a component in a marketed food would not be enough."
  • Since 2025, the earlier marketing does not have to have been lawful. In its NMN decision the FDA said it "will no longer evaluate whether the dietary supplement or food was lawfully marketed" when deciding who came first. The earlier product still has to have actually been a supplement or food sold in the US.
  • It covers the molecule, not just one product. According to the FDA's draft guidance, if a drug company studies one salt of a substance, any compound that delivers the same active substance is excluded too.
  • Stopping the drug program does not end it. The draft guidance says that withdrawing the drug trial application and stopping the trials "make no difference." Only an FDA regulation, like the one proposed for NAC, or a change in the law would lift the exclusion.
  • A new ingredient notification does not settle it. The FDA's draft guidance says that when it reviews a new dietary ingredient notification, it does not check whether the separate food provision, section 301(ll), applies, so an FDA "no objection" letter is not a clearance under that provision. The FDA has also used its replies to these notifications to say an ingredient is excluded, as it did for NAC in 2010 and NMN in 2022.

The ingredients it has affected

NAC: approved as a drug in 1963

NAC was approved in 1963 as Mucomyst, and the earliest supplement advertisement the FDA found is from 1991. The FDA said NAC was excluded in a 2001 letter (made public only in 2026), in a 2010 notification reply, and in 2020 warning letters to hangover products. In 2022 it issued guidance saying it would use enforcement discretion while it decided, and on November 17, 2026 it proposed a regulation that would make NAC a lawful supplement ingredient. Comments are due January 19, 2027. Our NAC rule explainer has the details, and our NAC guide covers what it does.

NMN: excluded in 2022, no longer excluded since 2025

In October and November 2022, the FDA told companies that NMN (nicotinamide mononucleotide) was excluded, because a drug company had been authorized to study it, and said earlier US supplement sales did not count because they lacked a required notification. The Natural Products Association and the Alliance for Natural Health USA petitioned the FDA in 2023, and the Natural Products Association sued in 2024.

On September 29, 2025, the FDA reversed course. It said it "is aware of evidence that NMN was marketed as a dietary supplement in the United States as early as 2017," before the drug authorization, and concluded "that NMN is not excluded from the definition of dietary supplement." It got there by dropping its requirement that earlier sales be lawful. See our NMN guide for the science.

CBD: still excluded

The FDA has concluded that CBD and THC "are excluded from the dietary supplement definition," because CBD is the active ingredient in the prescription drug Epidiolex, approved in 2018 for rare seizure disorders, and because substantial clinical investigations of it were made public first. In January 2023 the FDA said existing food and supplement rules are not appropriate for CBD and that "a new regulatory pathway for CBD is needed," which it would work on with Congress.

In April 2026, the FDA said it would not take action, on the basis of CBD content alone, against certain oral hemp-derived CBD products provided through a Medicare program under a physician's direction. That is a narrow enforcement policy, not a change in CBD's legal status. Separately, Congress narrowed the federal definition of hemp in November 2025, with the change scheduled to take effect a year later; that is a controlled-substance issue, not drug preclusion. Our CBD guide covers the evidence.

Red yeast rice: the court case that shaped the rule

Red yeast rice is rice fermented with a mold that produces monacolin K, which is chemically identical to lovastatin, the active ingredient in the cholesterol drug Mevacor, approved in 1987. In the late 1990s the FDA ruled that Cholestin, a red yeast rice product, was an unapproved drug. In Pharmanex v. Shalala (2000), a federal appeals court sided with the FDA, accepting that the word "article" in the law can mean an ingredient such as lovastatin, not only a finished drug product.

The FDA's current line, from a 2020 warning letter, is that red yeast rice "with enhanced or added lovastatin" cannot be sold as a supplement, while the FDA describes traditional red yeast rice as containing no more than trace amounts, if any. Because the FDA's line also covers products "promoted for lovastatin content," red yeast rice labels often avoid stating monacolin K content. The appeals court relied on a doctrine of deference to agencies that the Supreme Court overturned in 2024. The Supreme Court said earlier rulings like this one still stand, but some lawyers say courts may now look at the FDA's drug preclusion interpretations more closely in new cases. See our red yeast rice guide.

Pyridoxamine: excluded by a drug trial alone

Pyridoxamine is one of the natural forms of vitamin B6. A company filed a drug trial application in 1999 to study it as a kidney drug for people with diabetes. In 2005 the FDA tentatively concluded that pyridoxamine was excluded, and in 2009 it made that final. The drug has not been approved (we found no FDA approval for it as of November 2026), which shows that a drug investigation alone, without any approval, can remove an ingredient from supplements, even one found naturally in food.

Vinpocetine: a tentative case

In 2016 the FDA tentatively concluded that vinpocetine, a synthetic compound derived from a periwinkle alkaloid, is not a dietary ingredient, and also that it is excluded because it was authorized for drug investigation in 1981. In our searches through November 2026 we found no final FDA decision, and vinpocetine products remain on the market. In 2019 the FDA advised women who are pregnant or could become pregnant not to take vinpocetine.

Not every FDA action against a supplement ingredient is drug preclusion. DMHA, for example, was removed because the FDA concluded it is not a dietary ingredient at all, and products spiked with hidden drugs are an adulteration problem, not a question of which came first.

What happens to products on the shelf

A drug preclusion decision usually does not lead to a recall. What usually happens:

  • Warning letters. The FDA has often acted first against products that also make disease claims, such as the 2020 hangover products containing NAC.
  • Retailers pull products. According to trade press reports, Amazon removed NAC supplements in 2021 and restored them in 2022 after the FDA's enforcement discretion guidance, and it told sellers to remove NMN by March 2023 before the FDA's 2025 reversal.
  • Enforcement discretion. The FDA can decide not to act against products that are technically excluded while it reconsiders, as it did for NAC.
  • Long gray zones. Some ingredients, like vinpocetine, sit for years under a tentative finding.

The debate: protecting drug research or blocking supplements?

Supporters of the rule, including the FDA, point to its purpose: without it, drug companies could avoid drug review by calling a product a supplement, and generic supplement sales could undercut the incentive to fund expensive trials. The FDA also notes that a drug's safety review weighs risks against benefits, while a supplement safety assessment generally considers only risk, so a drug approval does not by itself show that an ingredient is suitable for supplement use.

Supplement industry groups argue that the rule as applied is unpredictable and can hand drug companies control over common substances. The Council for Responsible Nutrition (CRN), a trade group, petitioned the FDA in 2023 and, in a 2025 follow up, asked it to use the public date of trials rather than the confidential IND date and to exclude Phase 1 trials. The FDA denied the petition in September 2025, although on the same day it dropped its requirement that earlier marketing be lawful, a point CRN had also raised. CRN's chief executive, Steve Mister, said in November 2026 that "Drug preclusion is essentially a convergence of pharmaceutical and supplement economic interests; safety is only one factor in the decision."

In September 2026, Representative Diana Harshbarger introduced the Dietary Supplement Innovation Act (H.R. 10336), backed by several supplement trade groups. As introduced, it would:

  • replace "substantial clinical investigations" with Phase 2 or Phase 3 trials,
  • protect ingredients sold in the US before October 15, 1994,
  • end trial based preclusion if every related Phase 2 or 3 trial has been inactive or withdrawn for seven years, or the sponsor publicly drops the drug program,
  • require the FDA to consider differences in dose and route of administration, and
  • make FDA warning letters on this issue immediately reviewable in court.

As of November 2026 the latest action we could find was its referral to the House Energy and Commerce Committee; it has not been enacted. Not everyone in the industry agrees with it: the Natural Products Association has argued for a pure first-to-market rule, and some lawyers have pointed out drafting problems and warned that dropping the word "substantial" could let a small Phase 2 study block an ingredient as completely as a large one. In our searches through November 2026, we found little independent academic analysis of the rule.

What it means when you buy supplements

  • "Supplement" does not mean "not a drug." Some ingredients sold as supplements are identical to, or closely related to, drug ingredients. Red yeast rice can act like a statin, with the same muscle and interaction risks, so do not combine it with a statin, and tell your doctor if you take it.
  • Legal status can change. NMN went from being sold without an FDA objection, to excluded, to no longer excluded, in about three years. A product disappearing from one store does not necessarily mean it was found unsafe.
  • Legal status is not proof of benefit. Being allowed in supplements does not mean an ingredient works for any particular purpose, and being excluded does not mean it is unsafe.
  • Prescription versions are different products. Prescription CBD or acetylcysteine is made and dosed under drug standards; supplement products are not interchangeable with them.
  • Check interactions. If you take prescription medicines, ask your pharmacist about any supplement whose ingredient is also a drug.

For the broader picture, see our guide to how supplements are regulated under DSHEA and our supplement and drug interactions guide.

Frequently asked questions

What is drug preclusion?

Drug preclusion, also called the drug exclusion clause, is the part of US law that generally keeps an ingredient out of dietary supplements if it was approved as a drug, or authorized for substantial, public drug trials, before it was marketed as a supplement or food. The FDA can make exceptions by regulation.

Why is CBD not allowed as a dietary supplement?

The FDA has concluded that CBD is excluded because it is the active ingredient in the prescription drug Epidiolex and was the subject of substantial public drug investigations before it was marketed as a supplement or food. In 2023 the FDA said a new regulatory pathway is needed for CBD and that it would work with Congress on one.

Is NMN legal as a supplement?

It is no longer excluded, according to the FDA's current position. The FDA said in 2022 that NMN was excluded, but on September 29, 2025 it reversed itself, finding that NMN was marketed as a supplement in the US as early as 2017, before it was authorized for drug investigation. Like other supplement ingredients, NMN products still have to meet the usual supplement rules.

Is NAC legal as a supplement?

NAC is sold as a supplement, but the FDA still considers it technically excluded because it was approved as a drug in 1963. Since 2022 the FDA has used enforcement discretion, and in November 2026 it proposed a rule that would make NAC a lawful supplement ingredient once final. See our NAC rule explainer.

Why does red yeast rice not list its monacolin K content?

Monacolin K is identical to lovastatin, an approved cholesterol drug. The FDA treats red yeast rice with enhanced or added lovastatin as an unapproved drug, while it describes traditional red yeast rice as containing only trace amounts, and because promoting lovastatin content also draws FDA action, labels often avoid stating monacolin K content. Because it can act like a statin, do not combine it with statins and talk with your doctor before taking it. See our red yeast rice guide.

Can a natural vitamin be excluded from supplements?

Yes. Pyridoxamine, a natural form of vitamin B6, was excluded by the FDA in 2009 because a drug trial application for it was filed in 1999 and substantial, public drug trials followed before the FDA saw proof that it had been marketed as a supplement, even though the drug has not been approved.

How does the FDA decide what came first?

The FDA compares the date an ingredient was first marketed in the US as a supplement or food with the date a drug trial application for it took effect, or the drug approval date. Trial application dates are usually confidential, and the FDA decides case by case whether trials count as substantial clinical investigations, rather than using a bright-line test.

What is the Dietary Supplement Innovation Act?

H.R. 10336, introduced in September 2026, would change drug preclusion by tying it to Phase 2 or Phase 3 trials, protecting ingredients sold before October 15, 1994, ending preclusion after seven years of trial inactivity, and making FDA warning letters on the issue reviewable in court. As of November 2026 it had been referred to committee and not enacted.

Does drug preclusion mean an ingredient is unsafe?

No. Drug preclusion turns mainly on which came first, drug or supplement, not on a finding that the ingredient is harmful. An excluded ingredient is not necessarily unsafe, and an ingredient that is not excluded is not necessarily safe or effective.

The bottom line

Drug preclusion is a race: if a substance was approved or seriously studied as a drug before it was sold as a supplement or food, it generally cannot be a supplement. The rule exists to keep drugs from avoiding drug review and to protect the incentive to develop new medicines, and it explains the very different fates of NAC, NMN, CBD, red yeast rice and pyridoxamine.

How the FDA applies it, especially its reliance on confidential trial dates and a case by case "substantial" standard, is contested, and both a proposed NAC rule and a bill in Congress could change the landscape. For shoppers, the practical lesson is simple: a supplement label does not tell you whether an ingredient is also a drug, so check with a pharmacist when it matters.

VS
Reviewed for accuracy by
Vladimir Salamakha

B.S. in Chemistry, University of South Florida · a formulation scientist with 15 years developing compliant, evidence-based products across nutritional supplements and personal care. More about the author →

A quick note This article is general information about US supplement regulation, not legal or medical advice. Nothing here suggests that any supplement can diagnose, treat, cure, or prevent any disease. If you take prescription medicines, are pregnant or breastfeeding, or have a health condition, talk with your doctor or pharmacist before taking supplements, especially those whose ingredients are also drugs.
Sources
Federal Food, Drug, and Cosmetic Act sections 201(ff)(3) and 301(ll), 21 U.S.C. 321(ff) and 331(ll). law.cornell.edu. · US Food and Drug Administration. Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition. Proposed rule, 91 FR 73717, November 17, 2026; docket FDA-2025-N-2699. · US Food and Drug Administration. Dietary Supplements: New Dietary Ingredient Notifications and Related Issues, draft guidance for industry, October 2026 revision (replacing the August 2016 revised draft), section IV.D (questions on the drug exclusion). · US Food and Drug Administration. Response to citizen petition from the Natural Products Association and Alliance for Natural Health USA on NMN, docket FDA-2023-P-0872, September 29, 2025. · US Food and Drug Administration. Response to Council for Responsible Nutrition citizen petition, docket FDA-2023-P-1867, September 29, 2025; Council for Responsible Nutrition statements of September 29, 2025 and November 16, 2026 (crnusa.org) and March 7, 2025 supplemental submission. · US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), questions and answers; FDA statement, January 26, 2023; letter on hemp-derived cannabidiol products in medical research models, April 1, 2026. · Pharmanex v. Shalala, 221 F.3d 1151 (10th Cir. 2000); FDA consumer update on red yeast rice, August 10, 2007; FDA warning letter to Dr. Sam Robbins, Inc. (HFL Solutions), August 28, 2020. · US Food and Drug Administration. Request for Comment on the Status of Pyridoxamine, 70 FR 69976, November 18, 2005; FDA letter to Morgan, Lewis and Bockius responding to the BioStratum citizen petition, January 12, 2009, docket FDA-2005-P-0259. · US Food and Drug Administration. Request for Comment on the Status of Vinpocetine, 81 FR 61700, September 7, 2016; FDA vinpocetine information page. · Dietary Supplement Innovation Act, H.R. 10336, 119th Congress, introduced September 10, 2026. govinfo.gov. · Commentary: Venable LLP analyses of the NMN decision (October 2025) and H.R. 10336 (September 2026); Todd Harrison, Nutraceuticals World, September 24, 2026; Daniel Fabricant, NutraIngredients, October 2, 2026; NutraIngredients report on retailer removals, February 16, 2023.